Skip to main content

Day: January 24, 2022

Element Fleet Management Schedules Fourth Quarter and Full-Year 2021 Financial Results and Conference Call

Date: March 2, 2022 Time: 8:00 a.m. (Eastern Time) TORONTO, Jan. 24, 2022 (GLOBE NEWSWIRE) — Element Fleet Management Corp. (TSX: EFN) (“Element” or the “Company”), the largest pure-play automotive fleet manager in the world, will hold its fourth quarter and full-year 2021 results conference call and webcast for investors and analysts on Wednesday, March 2, 2022 at 8:00 a.m. ET. Element’s financial and operating results for the period will be issued after market close on Tuesday, March 1, 2022 and will be available on the Company’s website at www.elementfleet.com/investors. The conference call and webcast can be accessed as follows:Webcast:        https://services.choruscall.ca/links/elementfleet20220302.html     Telephone:   Click here to join the call most efficiently,or dial one of the following numbers to speak with...

Continue reading

IBC Advanced Alloys Strengthens its Balance Sheet by Paying Off the Mortgage on its Copper Alloys Manufacturing Facility

FRANKLIN, Ind., Jan. 24, 2022 (GLOBE NEWSWIRE) — IBC Advanced Alloys Corp. (“IBC” or the “Company”) (TSX-V: IB; OTCQB: IAALF) announces that it has completed payments on its $1.7 million mortgage term loan on its Copper Alloys manufacturing facility in Franklin, Ind. Paying off this mortgage is part of IBC’s primary corporate strategy of reducing its debt burden. “I am very pleased to announce that we have been able to pay off our sole mortgage as part of our ongoing effort to reduce corporate debt,” said Mark A. Smith, CEO and Director of IBC. “It is especially exciting that continuing strong sales across both of our operating divisions are strengthening IBC’s ability to generate cash flow and strengthen our balance sheet organically.” For more information on IBC and its innovative alloy products, go here. On Behalf of the Board...

Continue reading

APx Acquisition Corp. I Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing January 27, 2022

NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) — APx Acquisition Corp. I (the “Company”) announced today that, commencing January 27, 2022, holders of the units sold in the Company’s initial public offering of 17,250,000 units, completed on December 9, 2021, may elect to separately trade the shares of Class A ordinary shares and warrants included in the units. Those units not separated will continue to trade on the Nasdaq Global Market (“Nasdaq”) under the symbol “APXIU,” and the shares of Class A ordinary shares and warrants that are separated will trade on Nasdaq under the symbols “APXI” and “APXIW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s...

Continue reading

December 2021 Quarter Report

Perseus achieves record production and operating cashflowFigure 1Notional Operating CashflowFigure 2Quarterly Cash and Bullion MovementsFigure 1.1Yaouré Gold Project – Tenements and ProspectsFigure 1.2Sissingué Gold Mine and Bagoé Project – Tenements and ProspectsFigure 1.3Bagoé Gold Project – Main ProspectsFigure 1.4Edikan Gold Mine – Regional Geology, Tenements and ProspectsPERTH, Western Australia, Jan. 25, 2022 (GLOBE NEWSWIRE) — Perseus Mining Limited (“Perseus” or the “Company”) (TSX & ASX: PRU) reports on its activities for the three months’ period ended December 31, 2021 (the “Quarter”).PERFORMANCE INDICATOR UNIT CALENDAR2020 YEAR JUNE 2021HALF YEAR1 SEPTEMBER2021 QUARTER DECEMBER2021 QUARTER DECEMBER 2021HALF...

Continue reading

AnPac Bio Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

PHILADELPHIA, Jan. 24, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, announced today that it has received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) dated January 19, 2022 indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) set forth in the Nasdaq Rules for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(2)(C) requires companies to maintain a minimum MVPHS of US$15 million, and Listing Rule 5810(c)(3)(D) provides that a failure to meet the MVPHS requirement exists if the deficiency continues for a period of 30 consecutive business days. Based...

Continue reading

Brown & Brown, Inc. announces quarterly revenues of $738.5 million, an increase of 15.0%, diluted net income per share of $0.36 and Diluted Net Income Per Share – Adjusted of $0.42

DAYTONA BEACH, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) — Brown & Brown, Inc. (NYSE:BRO) (the “Company”) today announced its unaudited financial results for the fourth quarter and full year of 2021. Revenues for the fourth quarter of 2021 under U.S. generally accepted accounting principles (“GAAP”) were $738.5 million, increasing $96.4 million, or 15.0%, compared to the fourth quarter of the prior year, with commissions and fees increasing by 15.3% and Organic Revenue(1) increasing by 9.0%. Net income was $101.7 million, increasing $4.4 million, or 4.5%, and diluted net income per share increased to $0.36, or 5.9% as compared to the fourth quarter of the prior year. Diluted Net Income Per Share – Adjusted(2) increased to $0.42, or 31.3%, compared to the fourth quarter of the prior year. Revenues for...

Continue reading

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients

WORCESTER, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a hold, pending Chemistry, Manufacturing and Controls (“CMC”) clearance, on the Company’s Investigational New Drug (“IND”) application. Submitted in December 2021, the IND is to initiate a pivotal Phase 2 multicenter study to assess the safety, tolerability and efficacy of MB-207, Mustang’s lentiviral gene therapy for the treatment of patients with X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease, who have been previously...

Continue reading

SmartFinancial Announces Results for the Fourth Quarter 2021

Highlights for the Fourth Quarter of 2021Operating earnings1 of $0.52 and $2.39 per diluted common share for the 2021 fourth quarter and year end, respectively 31% increase in year-over-year operating earnings1 per diluted common share Net organic loan growth of over $75 million, a 12% annualized quarter-over-quarter increase Tangible book value per share1 of $19.26, a 4.8% annualized quarter-over-quarter increase Strategic Nashville, TN MSA2 enhancement with several senior relationship manager hires Gulf Coast Wealth Management team lift-out previously responsible for managing ~$350 million in AUM2 Completion of Sevier County Bancshares, Inc. (“SCB”) integration; five branch closures with near full realization of operational efficiencies Opening of Mobile, AL branch office and application approval of Auburn, Dothan and Montgomery branch...

Continue reading

Avista Corp. Fourth Quarter 2021 Earnings Conference Call and Webcast Announced

SPOKANE, Wash., Jan. 24, 2022 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) will hold its quarterly conference call and webcast to discuss fourth quarter 2021 results on Wednesday, February 23, 2022, at 10:30 a.m. Eastern Standard Time. A news release with fourth quarter 2021 earnings information will be issued at 7:05 a.m. Eastern Standard Time on February 23, 2022. This call can be accessed on Avista’s website at investor.avistacorp.com, or you can listen to the call by dialing (855) 806-8606, Confirmation number 9970246. A replay of the call will be available through March 2, 2022. Call (855) 859-2056, Confirmation number 9970246# to listen to the replay. The webcast will be archived for one year on the Avista Corp. web site at investor.avistacorp.com. Avista Corp. is an energy company involved in the production, transmission...

Continue reading

Arcimoto to Discuss Its Mission to Deliver Sustainable Transportation Solutions at the Baird Vehicle Technology & Mobility Conference on January 25

Arcimoto San Diego RentalsArcimoto to Discuss Its Mission to Deliver Sustainable Transportation Solutions at the Baird Vehicle Technology & Mobility Conference on January 25EUGENE, Ore., Jan. 24, 2022 (GLOBE NEWSWIRE) — Arcimoto, Inc.® (NASDAQ: FUV), makers of rightsized, outrageously fun, ultra-efficient electric vehicles for moving people and stuff, will showcase its family of products and share its vision for accelerating the transition to sustainable transportation at the 2022 Baird Vehicle Technology & Mobility Conference on January 25.2022 Baird Vehicle Technology & Mobility Conference   Date: Tuesday, January 25, 2022Presentation time: 10:15 a.m. ESTFormat: Presentation and 1-on-1 meetings (virtual)Registration: Investors may reach out to their Baird representative for registration...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.